SCHEMBL4675882

SCHEMBL4675882

O=C(Cc1sccc1S(=O)(=O)c1ccc(Cl)cc1)C(=O)c1nn[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 4/20 0.35
LMNA P02545 4/20 0.33
TBXA2R P21731 1/20 0.32
NPSR1 Q6W5P4 3/20 0.32
POLB P06746 1/20 0.32
ALDH1A1 P00352 3/20 0.32
CYP3A4 P08684 2/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32
MAPT P10636 2/20 0.32
NPC1 O15118 2/20 0.32
HTT P42858 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
AGTR1 P30556 1/20 0.32
RAB9A P51151 1/20 0.32
GPR55 Q9Y2T6 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
AKR1B1 P15121 1/20 0.32
ADRB2 P07550 1/20 0.31
HSP90AA1 P07900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674644 0.90 NPSR1 (0.43) NPSR1POLBALDH1A1HTTKMT2A
SCHEMBL4672385 0.89 MMP1 (0.35) CXCR3NPSR1SMN1; SMN2AKR1B1MEN1
SCHEMBL4676058 0.83 PTGER3 (0.35) LMNANPSR1POLBALDH1A1CYP3A4
SCHEMBL4671618 0.83 ALDH1A1 (0.36) CXCR3LMNATBXA2RNPSR1POLB
SCHEMBL4677001 0.80 MAPT (0.40) CXCR3LMNATBXA2RNPSR1POLB
SCHEMBL4675369 0.80 CXCR3 (0.36) CXCR3TBXA2RPOLBALDH1A1CYP3A4
SCHEMBL4672021 0.79 CXCR3 (0.35) CXCR3LMNATBXA2RNPSR1POLB
SCHEMBL4672144 0.78 CXCR3 (0.35) CXCR3TBXA2RPOLBALDH1A1CYP3A4
SCHEMBL4673305 0.78 CXCR3 (0.35) CXCR3LMNATBXA2RNPSR1ALDH1A1
SCHEMBL4673905 0.78 CXCR3 (0.35) CXCR3TBXA2RPOLBALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CXCR3 1130/4885LMNA 659/4885TBXA2R 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.